C53.8
BillableMalignant neoplasm of overlapping sites of cervix uteri
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C53.8 an HCC code?
Yes. C53.8 maps to Bladder, Colorectal, and Other Cancers under the CMS-HCC V28 risk adjustment model (and Colorectal, Bladder, and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C53.8
For C53.8to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C53.8 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C53.8 is the ICD-10-CM diagnosis code for malignant neoplasm of overlapping sites of cervix uteri. Cancer of the cervix that involves multiple overlapping sites or areas within the cervix. C53.8 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of female genital organs (c51-c58).
Under the CMS-HCC V28 risk adjustment model, C53.8 maps to Bladder, Colorectal, and Other Cancers (HCC 22) with a community, non-dual, aged base RAF weight of 0.363. Under the older CMS-HCC V24 model, C53.8 maps to Colorectal, Bladder, and Other Cancers (HCC 11) with a community, non-dual, aged base RAF weight of 0.307. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Use this code when the tumor spans both endocervical and exocervical regions. Because C53.8 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C53.8 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Use this code when the tumor spans both endocervical and exocervical regions
- •Document the extent of involvement and any invasion into surrounding tissues for accurate staging
Clinical Significance
Overlapping sites of cervix uteri indicates a malignancy that spans both the endocervix and exocervix, or involves multiple cervical subsites. This typically represents locally advanced cervical cancer where the tumor has extended beyond a single anatomical compartment. The overlapping designation has implications for treatment approach and staging.
Documentation Requirements
- ✓Documentation that tumor involves both endocervical and exocervical regions
- ✓Histological type and grade
- ✓FIGO staging reflecting the extent of disease
- ✓Depth of invasion and parametrial involvement
- ✓Lymph node status
- ✓Extension to vagina, uterine body, or other adjacent structures
- ✓Surgical specimen margins if applicable
Commonly Confused Codes
- •C53.0 — Endocervix only; use when tumor is confined to the inner cervical canal
- •C53.1 — Exocervix only; use when tumor is confined to the outer cervical surface
- •C53.9 — Cervix unspecified; use when the cervical subsite is unknown, not when multiple known sites are involved
- •C55 — Uterus, part unspecified; if tumor extends from cervix to corpus, determine the primary site per FIGO guidelines